| Ytd | 117.39% | |
| 1y | 140.38% |
| Open | 3.85 | Prev Close | 3.83 | Low | 1.90 | High | 4.00 | Mkt Cap | 152.69M |
| Vol | 7.02M | Avg Vol | 982.28K | EPS | -1.31 | P/E | -1.84 | Forward P/E | -1.40 |
| Beta | 1.31 | Short Ratio | 3.13 | Inst. Own | 56.55% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.43 | 200-d Avg | 2.34 | 1yr Est | 10.00 |
PYXS News
Wall Street analysts changed outlook on top names. For full changes, see our analyst ratings page. A
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage compa
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage compa
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MI
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) will likely be releasing its Q4 2025 results before
Shares of Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) have earned an average recommendatio
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage comp
Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) was the target of a large growth in short inte
Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) has been assigned a consensus recommendation o
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 st
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage comp
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage comp
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patien
Pyxis Oncology (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may p
Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pel
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage comp
On Friday, 404 stocks made new 52-week lows.
On Monday, 198 companies reached new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Monday, 671 companies achieved new lows for the year.
On Friday, 368 stocks hit new 52-week lows.
Wednesday's session saw 107 companies set new 52-week lows.
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid